Icilin
Icilin
Icilin is a synthetic chemical compound known for its ability to activate the cold receptors in the human body. It is structurally related to menthol, a naturally occurring compound that also induces a cooling sensation. Icilin is of interest in the field of neuroscience and pharmacology due to its unique properties and potential applications in pain management and sensory research.
Chemical Properties
Icilin is a member of the cyclohexanecarboxamide family. Its chemical structure is characterized by a cyclohexane ring attached to a carboxamide group, which is essential for its activity as a cold receptor agonist. The compound is typically synthesized in a laboratory setting and is not found in nature.
Mechanism of Action
Icilin exerts its effects by activating the transient receptor potential cation channel subfamily M member 8 (TRPM8), which is a cold and menthol receptor. This receptor is a type of ion channel that is activated by cold temperatures and cooling agents like menthol and icilin. When icilin binds to TRPM8, it induces a conformational change in the receptor, leading to the opening of the ion channel and an influx of calcium ions into the cell. This influx of calcium ions generates an electrical signal that is transmitted to the central nervous system, where it is perceived as a cooling sensation.
Applications
Icilin has been used in various scientific research studies to explore the mechanisms of cold sensation and pain. It serves as a tool for understanding the role of TRPM8 in thermoregulation and nociception. Additionally, icilin has potential therapeutic applications in the development of new analgesic drugs for the treatment of chronic pain conditions.
Safety and Toxicity
While icilin is a valuable research tool, its safety profile in humans is not well-established. Studies in animal models have shown that high doses of icilin can lead to adverse effects, including hypothermia and neurotoxicity. Therefore, caution is advised when handling and using icilin in experimental settings.
Related Pages
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD